Cardax (CDXI) Stock Price, News & Analysis

Company Overview

Cardax, Inc. is a biotechnology company focused on developing products designed to address inflammation and oxidative stress. The company’s research has centered on synthetic derivatives of astaxanthin, a naturally occurring antioxidant, with the goal of improving its bioavailability and potential therapeutic applications.

Cardax has developed CDX-085, an oral astaxanthin prodrug intended to release astaxanthin in the body. The company has also commercialized ZanthoSyn, a dietary supplement based on its astaxanthin technology and marketed for general health and wellness applications.

Cardax is based in Hawaii and has historically pursued both pharmaceutical development and consumer health products. Publicly available information about its current operations, geographic reach, and leadership is limited.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:CDXI
• CIK: 1544238
• Web: www.cardaxpharma.com
• Phone: (808) 457-1400
• Fax: 808-237-5901
• Employees: 10
• Year Founded: 2006

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 803,000
• Free Float: 566,000
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A